Frontiers reaches 6.4 on Journal Impact Factors

Case Report ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2018.00043

Melanoma unknown primary brain metastasis treatment with ECHO-7 oncolytic virus Rigvir: a case report

Guna Proboka1,  Andra Tilgase2*,  Sergejs Isajevs3, Agnija Rasa2 and Pēteris Alberts4
  • 1Latvian Oncology Centre, Riga East University hospital, Latvia
  • 2R&D, International Virotherapy Centre, Latvia
  • 3Department of Pathology, Riga East University hospital, Latvia
  • 4International Virotherapy Centre, Latvia

Melanoma is considered an aggressive malignancy with a tendency for forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of this disease. Melanoma brain metastases have many severe side effects and unfortunately, any disease related to the brain has limited therapeutic options due to the blood brain barrier. The course of the disease after completing a treatment course, and stopping the treatment, is complicated to predict and is difficult to obtain long-lasting remission. In this report we describe a female patient with unknown primary melanoma brain metastasis being treated with the oncolytic ECHO-7 virus Rigvir® after brain surgery. The patient has been stable, as monitored by MRI, for more than 3 years with the therapy still ongoing. The median expected overall survival from the time of diagnosis is approximately five months. Additional positive effect could have been gained from use of the intranasal administration route, which is considered effective due to the direct anatomical connection between the nasal cavity and the central nervous system. However, further studies are required to fully understand this mode of drug administration.

Keywords: Melanoma Brain Metastasis, melanoma unknown primary, blood brain barrier, oncolytic virus, ECHO-7 virus, intranasal, Rigvir

Received: 07 Dec 2017; Accepted: 09 Feb 2018.

Edited by:

Gordon Li, Stanford University, United States

Reviewed by:

Maria Caffo, Università degli Studi di Messina, Italy
Pierpaolo Peruzzi, Brigham and Women's Hospital, United States  

Copyright: © 2018 Proboka, Tilgase, Isajevs, Rasa and Alberts. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ms. Andra Tilgase, International Virotherapy Centre, R&D, Teātra street 9, Riga, LV-1021, Latvia, andra@virotherapy.eu